pharmaphorum

NOVEMBER 19, 2020

Lucentis (ranibizumab) was first FDA approved in 2006 for wet age-related macular degeneration (wet AMD) and has picked up approvals in related eye conditions ever since, although its patent expired in June.

FDA Approval 62

FDA Approval Marketing Drugs Clinical Development 62

The Pharma Data

MARCH 16, 2022

using SNAP-tag) involves labeling cell proteins with a fluorescent dye, thereby enabling researchers to observe how proteins interact in the living cell and where in the cell they are located. With Spirochrome, he commercialized fluorescent probes for cell biology, while with Covalys, he marketed SNAP-tag and other protein labeling methods.

Protein 52

Protein Scientist Gene Development 52

Delveinsight

DECEMBER 3, 2020

The agreement is for the investigational phase 1 gene therapy HMR59 that is given as a one-and-done shot into the eye to preserve vision in patients with geographic atrophy , which is a late-stage and severe form of age-related macular degeneration (AMD). Reversing vision loss by rolling back the ageing clock.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52